KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial. PMID 35998550 · Eur J Cancer · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. PMID 35990583 · EClinicalMedicine · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. PMID 35985981 · Eur Urol Oncol · 2022-Oct The record is a published erratum, which is an excluded publication type. It does not contain original trial results, regardless of the trial it refers to. Therefore, it is not eligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer. PMID 35965204 · Clin Breast Cancer · 2022-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. PMID 35933244 · Eur Urol · 2022-Oct The study is a randomized clinical trial in oncology (bladder cancer) and reports original results, but it compares surgical techniques (robot-assisted vs open radical cystectomy) and does not involve a drug-containing intervention. Additionally, the primary endpoint is 90-day morbidity/mortality, which is not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet all required criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study. PMID 35917052 · Breast Cancer Res Treat · 2022-Oct The study is a prospective, multi-center, non-randomized, controlled trial. It meets criteria for oncology, human, time-to-event endpoint, drug intervention, and original result, but it is explicitly non-randomized and does not specify a Phase III or II/III designation, which are mandatory for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. PMID 35902289 · Eur Urol · 2022-Oct The record describes a Phase 3 randomized controlled trial in human prostate cancer with disease-free survival as an endpoint, which is a primary time-to-event efficacy measure. However, the abstract and metadata do not explicitly confirm a drug-containing intervention (e.g., androgen deprivation therapy is implied but not explicitly detailed as a randomized drug intervention versus a non-drug comparator in the available text). Without explicit evidence of a drug intervention, eligibility cannot be confirmed.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The development of a culturally sensitive educational video: How to facilitate informed decisions on cervical cancer screening among Turkish- and Moroccan-Dutch women. PMID 35866200 · Health Expect · 2022-Oct The record describes the development process of an educational video, not the results of a clinical trial with a drug intervention and time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). PMID 35844026 · Front Med · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. PMID 35842199 · Ann Oncol · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Reminiscence therapy-based care program serves as an optional nursing modality in alleviating anxiety and depression, improving quality of life in surgical prostate cancer patients. PMID 35841489 · Int Urol Nephrol · 2022-Oct The trial meets criteria for oncology, human, randomized, original result, and time-to-event endpoints. However, it is ineligible because the intervention is non-drug (a nursing/reminiscence therapy program), and no drug-containing intervention is present, which is a required criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. PMID 35840747 · Bone Marrow Transplant · 2022-Oct While the study meets criteria for oncology, human, randomized, time-to-event, drug intervention, and original result, the explicit trial phase required for inclusion (Phase III/IIIb or Phase II/III) is not established in the provided metadata. Therefore, the record cannot be confirmed as eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. PMID 35803294 · Lancet Gastroenterol Hepatol · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial. PMID 35780048 · Eur Urol Oncol · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. PMID 35776183 · Support Care Cancer · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. PMID 35772665 · Ann Oncol · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. PMID 35772447 · Lancet Infect Dis · 2022-Oct The study is a Phase 2 randomized controlled trial of a tuberculosis vaccine (VPM1002 vs BCG) in neonates. It is not an oncology study, the intervention is not a drug, and the primary endpoint is safety/immunogenicity, not a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Virtual clinics in gynaecology - Can we shorten the wait? A randomised controlled trial implementing a novel care pathway for postmenopausal bleeding. PMID 35754324 · Aust N Z J Obstet Gynaecol · 2022-Oct The record is not eligible because it is not an oncology study (it addresses postmenopausal bleeding, a symptom, not a malignant neoplasm), lacks a drug-containing intervention, and does not meet the required phase criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough. PMID 35752582 · Allergol Int · 2022-Oct Study is not oncology; it evaluates gefapixant for chronic cough, not cancer. Even if oncology, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). Primary objective is safety/tolerability, secondary is quality of life.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). PMID 35739299 · Br J Cancer · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]. PMID 35732920 · Strahlenther Onkol · 2022-Oct Metadata confirms oncology, human, randomized, and phase III trial. However, no explicit time-to-event endpoint (e.g., OS, PFS, HR, Kaplan-Meier) or drug intervention is reliably established from the title or metadata. 'Multimodality treatment' could include non-drug modalities (radiation, surgery). Therefore, eligibility cannot be determined from the provided record.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. PMID 35714812 · J Hepatol · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Trial protocol for COLO-DETECT: A randomized controlled trial of lesion detection comparing colonoscopy assisted by the GI Genius™ artificial intelligence endoscopy module with standard colonoscopy. PMID 35680613 · Colorectal Dis · 2022-Oct 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Novel Electromagnetic Navigation Bronchoscopy System for the Diagnosis of Peripheral Pulmonary Nodules: A Randomized Clinical Trial. PMID 35679184 · Ann Am Thorac Soc · 2022-Oct The study is a randomized oncology trial in humans with original results, but it is not a drug-containing intervention trial, is not phase III/IIIb or phase II/III, and the primary endpoint is diagnostic yield (a non-time-to-event measure).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. PMID 35674861 · Clin Rheumatol · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients. PMID 35656795 · Histol Histopathol · 2022-Oct The study is a retrospective biomarker expression analysis of CLDN18.2 in pancreatic cancer specimens, evaluating its association with clinicopathological features and survival. While it mentions CLDN18.2-targeted drugs are in clinical trials, this specific study does not test a drug intervention. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. PMID 35643956 · Arthritis Rheumatol · 2022-Oct The study is not an oncology trial; it is a non-interventional safety analysis in rheumatoid arthritis patients, not a randomized Phase II/III or III/IIIb drug intervention trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Contrast-enhanced CT radiomics for prediction of recurrence-free survival in gallbladder carcinoma after surgical resection. PMID 35612664 · Eur Radiol · 2022-Oct The study fails multiple eligibility criteria: it is not a randomized trial (despite a 'randomized' publication tag, the randomization described is for retrospective cohort splitting, not for allocating a therapeutic intervention), it is not a Phase III/IIIb or Phase II/III trial, and it does not involve a drug-containing intervention. It is a prognostic modeling study, not an interventional efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment. PMID 35610532 · J Endocrinol Invest · 2022-Oct This is a randomized trial for hyperthyroidism (non-oncology). It does not involve a malignant neoplasm, and the endpoint is time to euthyroidism (not a standard oncology time-to-event efficacy endpoint like OS, PFS, DFS, etc.). The intervention (methimazole) is a drug, but the context is non-oncology.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial. PMID 35554955 · Hematol Oncol · 2022-Oct The study is a randomized, phase III trial with drug intervention and human oncology patients, but the primary efficacy endpoint is not a standard oncologic time-to-event endpoint (OS, PFS, etc.). The primary endpoint is platelet engraftment, which is a supportive care endpoint. While OS and PFS are reported as secondary endpoints, the study is not designed to evaluate them as primary or key secondary efficacy outcomes for the malignancy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial. PMID 35543079 · J Eur Acad Dermatol Venereol · 2022-Oct The study is a randomized, controlled, prospective trial in human oncology (basal cell carcinoma). However, it compares two non-drug physical treatment modalities (curettage vs. cryosurgery) and does not involve a drug-containing intervention. The primary endpoint is clinical clearance rate at 1 year, a binary outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS, RFS, TTP, or a Kaplan-Meier/HR analysis). It also does not meet the requirement for a Phase III/IIIb or definitive Phase II/III trial; the phase is not explicitly stated but appears to be a non-inferiority trial without a phase designation. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial. PMID 35403245 · J Clin Pharmacol · 2022-Oct 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Silver Nitrate-coated versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial. PMID 35363591 · Ann Am Thorac Soc · 2022-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial. PMID 35226933 · Ultraschall Med · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study. PMID 35130417 · Cancer Res Treat · 2022-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A qualitative exploration of the feasibility and acceptability of Meaning-Centered Psychotherapy for Cancer Caregivers. PMID 35078552 · Palliat Support Care · 2022-Oct The record describes a qualitative feasibility study of a psychosocial intervention for cancer caregivers, not a randomized trial of a drug with a time-to-event efficacy endpoint in oncology patients.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. PMID 34856706 · Cancer Res Treat · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Proposing a novel care program: reminiscence therapy involved care for anxiety, depression, and quality of life in postoperative cervical cancer patients. PMID 34716885 · Ir J Med Sci · 2022-Oct The record describes a randomized trial in oncology patients with a time-to-event efficacy endpoint (OS), but the intervention is a non-drug therapy (reminiscence therapy), not a drug-containing intervention. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exercise effects on DNA methylation in EVL, CDKN2A (p14, ARF), and ESR1 in colon tissue from healthy men and women. PMID 34550860 · Epigenetics · 2022-Oct This is a randomized controlled trial in healthy humans studying the effect of exercise on DNA methylation in colon tissue, with a potential link to colon cancer risk. However, it is not a Phase III or definitive trial of a drug intervention for cancer treatment. The primary endpoint is changes in DNA methylation, not a time-to-event efficacy outcome (like OS, PFS, DFS, etc.) in cancer patients. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiomics-based prediction of response to immune checkpoint inhibitor treatment for solid cancers using computed tomography: a real-world study of two centers. PMID 36451109 · BMC Cancer · 2022-Nov-30 The record describes a predictive model study using radiomics to predict response to immune checkpoint inhibitors, with survival analysis as a secondary evaluation. While it mentions a drug intervention and time-to-event endpoint, it is not a Phase III or Phase II/III randomized controlled trial comparing drug regimens. The randomization refers to dataset splitting (training/validation), not patient allocation to treatment arms in a trial. Therefore, it does not meet the eligibility criteria for a definitive-phase randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age. PMID 35358015 · Hum Vaccin Immunother · 2022-Nov-30 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. PMID 36447152 · BMC Cancer · 2022-Nov-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. PMID 36556355 · Life (Basel) · 2022-Nov-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. PMID 36434615 · BMC Cancer · 2022-Nov-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Outcomes of a Comprehensive Mobile Smoking Cessation Program With Nicotine Replacement Therapy in Adult Smokers: Pilot Randomized Controlled Trial. PMID 36257323 · JMIR Mhealth Uhealth · 2022-Nov-24 The study is a randomized trial of a smoking cessation intervention (nicotine replacement therapy) in humans, but it is not an oncology trial (smoking cessation/prevention). The primary endpoint is app engagement (total app openings), and cessation outcomes (point prevalence abstinence, continuous abstinence) are categorical proportions at fixed time points, not time-to-event endpoints like OS, PFS, DFS, EFS, RFS, TTP, or analyses with Kaplan-Meier/HR. It does not meet the oncology or time-to-event criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgical site infection after intracorporeal anastomosis for left-sided colon cancer: study protocol for a non-inferiority multicenter randomized controlled trial (STARS). PMID 36415000 · Trials · 2022-Nov-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma. PMID 36411723 · Ann Transplant · 2022-Nov-22 The record describes a non-interventional follow-up study to a prior randomized trial, not a primary report of a Phase III/IIIb trial. The primary efficacy outcome is HCC recurrence (binary, non-time-to-event). No time-to-event endpoint (OS, PFS, etc.) is reported or analyzed with Kaplan-Meier or HR. Therefore, it fails the required criteria for oncology Phase III/IIIb trials with a drug intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial. PMID 36074703 · Br J Surg · 2022-Nov-22 The study is a Phase III randomized trial in oncology but fails two key eligibility criteria: (1) it lacks a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is SLN identification rate), and (2) the intervention is not drug-containing (it compares diagnostic mapping techniques).
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of Propofol versus Sevoflurane Anesthesia on Acute Kidney Injury after Lung Transplantation Surgery: A Prospective Randomized Controlled Trial. PMID 36431341 · J Clin Med · 2022-Nov-21 The study is a randomized trial in human subjects reporting primary results, but it is not an oncology study (focused on lung transplantation and acute kidney injury) and does not involve a drug intervention for cancer treatment. The primary outcome is acute kidney injury, not a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BREAst Cancer Personalised NuTrition (BREACPNT): dietary intervention in breast cancer survivors treated with endocrine therapy - a protocol for a randomised clinical trial. PMID 36410828 · BMJ Open · 2022-Nov-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -